ChemicalBook > CAS DataBase List > Research Grade Lifastuzumab(DHB65401)
Research Grade Lifastuzumab(DHB65401)
- Product Name
- Research Grade Lifastuzumab(DHB65401)
- CAS No.
- 1615697-16-9
- Chemical Name
- Research Grade Lifastuzumab(DHB65401)
- Synonyms
- Research Grade Lifastuzumab;Research Grade Lifastuzumab(DHB65401)
- CBNumber
- CB812784022
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Research Grade Lifastuzumab(DHB65401) Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Research Grade Lifastuzumab(DHB65401) Chemical Properties,Usage,Production
Uses
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity[1].
References
[1] Banerjee S, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29(4):917-923. DOI:10.1093/annonc/mdy023
Research Grade Lifastuzumab(DHB65401) Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Research Grade Lifastuzumab(DHB65401) Suppliers
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 9785721070
- info@cellsciences.com
- Country
- China
- ProdList
- 6308
- Advantage
- 58
- Tel
- 18312220236
- Country
- CHINA
- ProdList
- 178
- Advantage
- 58
1615697-16-9, Research Grade Lifastuzumab(DHB65401)Related Search:
Vapaliximab
Actoxumab
Drozitumab
Tiragolumab
Tilvestamab
Elezanumab
Odronextamab
Dalotuzumab
Gemtuzumab
Zilovertamab